Welcome to our dedicated page for Nurix Therapeutics SEC filings (Ticker: NRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nurix Therapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines. Its 8-K reports furnish quarterly and annual financial results, corporate presentations, clinical-program updates for bexobrutideg and pipeline programs, and other material events tied to research, development and financing activity.
The company’s SEC disclosures also cover its common stock listed on the Nasdaq Global Market, shelf registration and at-the-market equity distribution arrangements, underwritten equity offerings, and use-of-proceeds language tied to clinical development and research programs. Proxy and governance filings document board composition, director appointments, compensation programs, committee assignments and annual stockholder meeting matters.
Nurix Therapeutics entered a global license and collaboration agreement with Roche for bexobrutideg (NX-5948), an investigational oral BTK degrader for cancers and immune diseases. Roche will pay Nurix a $700 million upfront and up to $2.3 billion in potential development, regulatory, and sales milestones.
The partners will co-develop and co-commercialize bexobrutideg in the U.S., sharing development costs 40% Nurix and 60% Roche and splitting U.S. profits and losses 50/50. Outside the U.S., Roche will lead commercialization while Nurix receives tiered royalties from the low teens to the high teens. The deal becomes effective after required antitrust clearances.
Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an open-market sale and an option exercise involving the company’s common stock. She sold 8,148 shares of common stock at a weighted average price of $16.5995 per share under a pre-arranged Rule 10b5-1 trading plan, with sale prices ranging from $16.35 to $17.10. In a related move, she exercised employee stock options covering 3,422 shares at an exercise price of $1.86 per share, converting them into common stock. Following these transactions, she directly holds 13,579 shares of common stock and 5,221 employee stock options.
Christine Ring submitted a Form 144 notice relating to sales of Common Stock. The filing lists multiple 10b5-1 sales executed in April–May 2026, with individual transactions such as 05/04/2026: 3,368 shares ($57,118.25) and 05/01/2026: 5,394 shares ($90,406.68).
The filing also lists securities acquired earlier by means of Restricted Stock Units (678 shares, 05/02/2022), an Employee Stock Purchase Plan (4,048 shares, 08/11/2020), and previously exercised options (3,422 shares, 10/01/2019), each shown with its grant/acquisition date.
Nurix Therapeutics director Paul M. Silva received a new stock option grant covering 31,250 shares of Common Stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036.
The option vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, in each case only if Silva continues providing service to the company through the vesting date. Following this grant, he holds stock options for 31,250 shares directly.
Nurix Therapeutics director Edward C. Saltzman received a stock option grant for 31,250 shares of common stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036. All 31,250 underlying shares are reported as held directly after this award.
The option vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, assuming Mr. Saltzman continues to provide service to Nurix through the vesting date. This is a compensation-related grant, not an open-market share purchase or sale.
Nurix Therapeutics, Inc. director Judith A. Reinsdorf received a grant of stock options covering 31,250 shares of common stock. The options have an exercise price of $15.86 per share and expire on May 14, 2036. The entire award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, subject to her continued service, giving her 31,250 options beneficially owned after this grant.
Nurix Therapeutics director David L. Lacey received a grant of stock options covering 31,250 shares of common stock. The options have an exercise price of $15.86 per share and are held directly. Following this award, he holds options on 31,250 shares.
The option grant vests in full on the earlier of the company’s next annual stockholder meeting or May 15, 2027, in each case only if he continues providing service to Nurix on that vesting date. The options expire on May 14, 2036 if not exercised.
Nurix Therapeutics director Anil Kapur received a stock option grant covering 31,250 shares of common stock. The option has an exercise price of $15.86 per share and expires on May 14, 2036. This is a compensation-related award, not an open-market purchase.
The option vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, as long as Kapur continues providing service to Nurix through the vesting date. After this grant, his directly held option position from this award totals 31,250 underlying shares.
Nurix Therapeutics, Inc. reported a Form 4 showing director Roger D. Dansey received a grant of stock options for 31,250 shares of common stock at an exercise price of $15.86 per share. The option vests 100% on the earlier of the next annual stockholder meeting or May 15, 2027, subject to continued service, and expires on May 14, 2036. This is a compensation-related award, not an open-market trade.
Nurix Therapeutics director Roy D. Baynes received a grant of 31,250 stock options to buy Nurix common stock. The options have an exercise price of $15.86 per share and expire on May 14, 2036, providing long-term equity-based compensation.
The award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, so long as Baynes continues to provide service through the vesting date. After this grant, he holds 31,250 derivative securities linked to Nurix common stock directly.